1. |
Zheng R, Zeng H, Zhang S, et al. Estimates of cancer incidence and mortality in China, 2013. Chin J Cancer, 2017, 36(1): 66.
|
2. |
Zeng XY, Yin YP, Xiao H, et al. Clinicopathological characteristics and prognosis of hepatoid adenocarcinoma of the stomach: Evaluation of a pooled case series. Curr Med Sci, 2018, 38(6): 1054-1061.
|
3. |
Ishikura H, Fukasawa Y, Ogasawara K, et al. An AFP-producing gastric carcinoma with features of hepatic differentiation. A case report. Cancer, 1985, 56(4): 840-848.
|
4. |
Yang J, Wang R, Zhang W, et al. Clinicopathological and prognostic characteristics of hepatoid adenocarcinoma of the stomach. Gastroenterol Res Pract, 2014, 2014: 140587.
|
5. |
Zhao M, Sun L, Lai JZ, et al. Expression of RNA-binding protein LIN28 in classic gastric hepatoid carcinomas, gastric fetal type gastrointestinal adenocarcinomas, and hepatocellular carcinomas: An immunohistochemical study with comparison to SALL4, alpha-fetoprotein, glypican-3, and Hep Par1. Pathol Res Pract, 2018, 214(10): 1707-1712.
|
6. |
Fakhruddin N, Bahmad HF, Aridi T, et al. Hepatoid adenocarcinoma of the stomach: A challenging diagnostic and therapeutic disease through a case report and review of the literature. Front Med (Lausanne), 2017, 4: 164.
|
7. |
Wang Y, Sun L, Li Z, et al. Hepatoid adenocarcinoma of the stomach: a unique subgroup with distinct clinicopathological and molecular features. Gastric Cancer, 2019 Apr 15. doi: 10.1007/s10120-019-00965-5.
|
8. |
Tsuruta S, Ohishi Y, Fujiwara M, et al. Gastric hepatoid adenocarcinomas are a genetically heterogenous group; most tumors show chromosomal instability, but MSI tumors do exist. Hum Pathol, 2019, 88: 27-38.
|
9. |
Xiao C, Wu F, Jiang H, et al. Hepatoid adenocarcinoma of the stomach: Nine case reports and treatment outcomes. Oncol Lett, 2015, 10(3): 1605-1609.
|
10. |
Zhou RU, Cai Y, Yang YI, et al. Hepatoid adenocarcinoma of the stomach: A case report and review of the literature. Oncol Lett, 2015, 9(5): 2126-2128.
|
11. |
Kumashiro Y, Yao T, Aishima S, et al. Hepatoid adenocarcinoma of the stomach: histogenesis and progression in association with intestinal phenotype. Hum Pathol, 2007, 38(6): 857-863.
|
12. |
Baek SK, Han SW, Oh DY, et al. Clinicopathologic characteristics and treatment outcomes of hepatoid adenocarcinoma of the stomach, a rare but unique subtype of gastric cancer. BMC Gastroenterol, 2011, 11: 56.
|
13. |
Inagawa S, Shimazaki J, Hori M, et al. Hepatoid adenocarcinoma of the stomach. Gastric Cancer, 2001, 4(1): 43-52.
|
14. |
Ishikura H, Kirimoto K, Shamoto M, et al. Hepatoid adenocarcinomas of the stomach. An analysis of seven cases. Cancer, 1986, 58(1): 119-126.
|
15. |
Kinjo T, Taniguchi H, Kushima R, et al. Histologic and immunohistochemical analyses of α-fetoprotein-producing cancer of the stomach. Am J Surg Pathol, 2012, 36(1): 56-65.
|
16. |
Su JS, Chen YT, Wang RC, et al. Clinicopathological characteristics in the differential diagnosis of hepatoid adenocarcinoma: a literature review. World J Gastroenterol, 2013, 19(3): 321-327.
|
17. |
Terracciano LM, Glatz K, Mhawech P, et al. Hepatoid adenocarcinoma with liver metastasis mimicking hepatocellular carcinoma: an immunohistochemical and molecular study of eight cases. Am J Surg Pathol, 2003, 27(10): 1302-1312.
|
18. |
Akiyama S, Tamura G, Endoh Y, et al. Histogenesis of hepatoid adenocarcinoma of the stomach: molecular evidence of identical origin with coexistent tubular adenocarcinoma. Int J Cancer, 2003, 106(4): 510-515.
|
19. |
任为正, 苏茂生, 杜晓霞, 等. 胃肝样腺癌 25 例. 中华肝胆外科杂志, 2016, 22(10): 665-667.
|
20. |
Wennerberg AE, Nalesnik MA, Coleman WB. Hepatocyte paraffin 1: a monoclonal antibody that reacts with hepatocytes and can be used for differential diagnosis of hepatic tumors. Am J Pathol, 1993, 143(4): 1050-1054.
|
21. |
Chu PG, Ishizawa S, Wu E, et al. Hepatocyte antigen as a marker of hepatocellular carcinoma: an immunohistochemical comparison to carcinoembryonic antigen, CD10, and alpha-fetoprotein. Am J Surg Pathol, 2002, 26(8): 978-988.
|
22. |
Osada M, Aishima S, Hirahashi M, et al. Combination of hepatocellular markers is useful for prognostication in gastric hepatoid adenocarcinoma. Hum Pathol, 2014, 45(6): 1243-1250.
|
23. |
Zhang J, Tam WL, Tong GQ, et al. Sall4 modulates embryonic stem cell pluripotency and early embryonic development by the transcriptional regulation of Pou5f1. Nat Cell Biol, 2006, 8(10): 1114-1123.
|
24. |
Ushiku T, Shinozaki A, Shibahara J, et al. SALL4 represents fetal gut differentiation of gastric cancer, and is diagnostically useful in distinguishing hepatoid gastric carcinoma from hepatocellular carcinoma. Am J Surg Pathol, 2010, 34(4): 533-540.
|
25. |
McWhorter ES, West RC, Russ JE, et al. LIN28B regulates androgen receptor in human trophoblast cells through Let-7c. Mol Reprod Dev, 2019, 86(9): 1086-1093.
|
26. |
Sentani K, Oue N, Sakamoto N, et al. Gene expression profiling with microarray and SAGE identifies PLUNC as a marker for hepatoid adenocarcinoma of the stomach. Mod Pathol, 2008, 21(4): 464-475.
|
27. |
牟安娜, 王婷. 胃肝样腺癌影像学表现 1 例. 中国医学影像技术, 2019, 35(6): 959.
|
28. |
Lin YY, Chen CM, Huang YH, et al. Liver metastasis from hepatoid adenocarcinoma of the stomach mimicking hepatocellular carcinoma: Dynamic computed tomography findings. World J Gastroenterol, 2015, 21(48): 13524-13531.
|
29. |
Lin CY, Yeh HC, Hsu CM, et al. Clinicopathologial features of gastric hepatoid adenocarcinoma. Biomed J, 2015, 38(1): 65-69.
|
30. |
Søreide JA, Greve OJ, Gudlaugsson E, et al. Hepatoid adenocarcinoma of the stomach-proper identification and treatment remain a challenge. Scand J Gastroenterol, 2016, 51(6): 646-653.
|
31. |
Sano T, Izuishi K, Takebayashi R, et al. Surgical approach for extrahepatic metastasis of HCC in the abdominal cavity. Hepatogastroenterology, 2011, 58(112): 2067-2070.
|
32. |
Lin HJ, Hsieh YH, Fang WL, et al. Clinical manifestations in patients with alpha-fetoprotein-producing gastric cancer. Curr Oncol, 2014, 21(3): e394-e399.
|
33. |
Akazawa Y, Saito T, Hayashi T, et al. Next-generation sequencing analysis for gastric adenocarcinoma with enteroblastic differentiation: emphasis on the relationship with hepatoid adenocarcinoma. Hum Pathol, 2018, 78: 79-88.
|
34. |
Arora K, Bal M, Shih A, et al. Fetal-type gastrointestinal adenocarcinoma: a morphologically distinct entity with unfavourable prognosis. J Clin Pathol, 2018, 71(3): 221-227.
|
35. |
Kwon MJ, Byeon S, Kang SY, et al. Gastric adenocarcinoma with enteroblastic differentiation should be differentiated from hepatoid adenocarcinoma: A study with emphasis on clear cells and clinicopathologic spectrum. Pathol Res Pract, 2019, 215(9): 152525.
|
36. |
Liu X, Sheng W, Wang Y. An analysis of clinicopathological features and prognosis by comparing hepatoid adenocarcinoma of the stomach with AFP-producing gastric cancer. J Surg Oncol, 2012, 106(3): 299-303.
|
37. |
Wang W, Zheng C, Fang C, et al. Time trends of clinicopathological features and surgical treatment for gastric cancer: Results from 2 high-volume institutions in southern China. Surgery, 2015, 158(6): 1590-1597.
|
38. |
苏伟, 张胜龙, 王文涛, 等. 胃肝样腺癌的 MDT 讨论. 中国普外基础与临床杂志, 2018, 25(2): 213-220.
|
39. |
Zeng X, Zhang P, Xiao H, et al. Clinicopathological features and prognosis of intestinal hepatoid adenocarcinoma: evaluation of a pooled case series. Oncotarget, 2017, 9(2): 2715-2725.
|
40. |
Simmet V, Noblecourt M, Lizée T, et al. Chemotherapy of metastatic hepatoid adenocarcinoma: Literature review and two case reports with cisplatin etoposide. Oncol Lett, 2018, 15(1): 48-54.
|
41. |
Kamoshida S, Suzuki M, Sakurai Y, et al. Expression of chemoresistance-related proteins in alpha-fetoprotein-producing adenocarcinoma of the digestive organs. Oncol Rep, 2006, 16(4): 721-727.
|
42. |
Mahajan V, Gupta N, Gupta S, et al. Hepatoid adenocarcinoma of stomach: case report of a rare histological variant. Indian J Pathol Microbiol, 2014, 57(1): 116-119.
|
43. |
Xie Y, Zhao Z, Li P, et al. Hepatoid adenocarcinoma of the stomach is a special and easily misdiagnosed or missed diagnosed subtype of gastric cancer with poor prognosis but curative for patients of pN0/1: the experience of a single center. Int J Clin Exp Med, 2015, 8(5): 6762-6772.
|
44. |
Fujimoto M, Matsuzaki I, Nishino M, et al. HER2 is frequently overexpressed in hepatoid adenocarcinoma and gastric carcinoma with enteroblastic differentiation: a comparison of 35 cases to 334 gastric carcinomas of other histological types. J Clin Pathol, 2018, 71(7): 600-607.
|
45. |
Boland CR. The molecular biology of gastrointestinal cancer: implications for diagnosis and therapy. Gastrointest Endosc Clin N Am, 2008, 18(3): 401-413.
|
46. |
张丽霞, 刘淑贞, 邓新娜, 等. 阿帕替尼治疗胃肝样腺癌 1 例. 医学研究生学报, 2018, 31(4): 416-418.
|
47. |
Fang YU, Wang L, Yang N, et al. Successful multimodal therapy for an α-fetoprotein-producing gastric cancer patient with simultaneous liver metastases. Oncol Lett, 2015, 10(5): 3021-3025.
|
48. |
Vogl TJ, Gruber-Rouh T, Eichler K, et al. Repetitive transarterial chemoembolization (TACE) of liver metastases from gastric cancer: local control and survival results. Eur J Radiol, 2013, 82(2): 258-263.
|
49. |
Liu X, Cheng Y, Sheng W, et al. Analysis of clinicopathologic features and prognostic factors in hepatoid adenocarcinoma of the stomach. Am J Surg Pathol, 2010, 34(10): 1465-1471.
|
50. |
Hirajima S, Komatsu S, Ichikawa D, et al. Liver metastasis is the only independent prognostic factor in AFP-producing gastric cancer. World J Gastroenterol, 2013, 19(36): 6055-6061.
|
51. |
王雅坤, 张小田. 产甲胎蛋白胃癌和胃肝样腺癌. 中华肿瘤杂志, 2017, 39(11): 801-807.
|
52. |
王闫飞, 赖玉梅, 寇芙蓉, 等. 30 例胃肝样腺癌患者临床病理特点及预后分析. 中国肿瘤临床, 2018, 45(7): 355-361.
|